Actus Oncology targeted mini-proteins de-risk radiopharma
Actus Oncology's mini-protein radiopharmaceutical platform provides high-target precision, early imaging validation, and structural protection from generic and Chinese competition.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.